Quick Answer
The buyer decides peptide approvals, not the research-use-only label. Processors still boarding this category weigh lab sales apart from consumer sales, so splitting those channels helps more than any disclaimer.
Consumer demand already flows through prescriptions. Grand View Research put GLP-1 peptides at 43.32% of the U.S. retail peptide therapeutics market in 2024.
Key Points
- Under 21 CFR 312.160, a shipper of lab research drugs must confirm the recipient runs such tests and keep each recipient's records for 2 years.
- In an April 2025 Global Legal Law Firm video, banks flagged peptide merchants onboarded as research labs for a "violation of standards," though their products had not changed.
- SeamlessChex requires established volume of at least $25,000 a month, then looks for lab and consumer sales split onto separate storefronts and merchant IDs.
Lab orders and consumer orders look different to an underwriter, even when the vial inside is the same.
Peptide sellers keep asking which disclaimer wording gets them approved. I think that is the wrong question. The better question is who actually pays for your orders, and whether those buyers match what your application says.
Regulation will not settle it soon. The FDA is reviewing whether compounding pharmacies may prepare some wellness peptides, yet Dr. Jess Steier argues that a new regulatory category "isn't approval and isn't new evidence." The research section below walks through these findings. So the case below rests on what banks, practitioners and processors have said on record, starting with the label itself.
A research-use-only label tells a processor what you call your product. Before applying, ask who actually pays for your orders, because that is the gap an underwriter will probe. That gap matters because consumer interest keeps growing: in 2025, 19.5% of surveyed U.S. consumers said they were considering a GLP-1 drug in the next year. A lab certificate claiming "99% pure" does not close that gap either, because a purity figure describes the vial, not the customer. And as UConn's C. Michael White notes, research-labeled sellers cannot legally tell buyers how to use what they sell.
Why doesn't a research-use-only label protect a peptide merchant account?
A research-use-only label describes the product, not the buyer. Underwriters price who actually pays and how money moves, so the disclaimer rarely carries an approval by itself.
Before you lean on the label, ask yourself three questions:
- Who is the real end buyer: a laboratory, an institution, or a consumer?
- Do your checkout flow, marketing and order data point to that same buyer?
- Would a bank reviewer reading your site reach the answer you wrote on your application?
UConn pharmacist and clinical pharmacologist C. Michael White describes "for research purposes only" as a legal workaround in an August 21, 2026 UConn Today piece. Sellers use it to sidestep FDA oversight, which means they cannot legally tell buyers how to use what they sell. His study in Public Health Reports found that laypeople completed fewer than half the steps correctly when preparing and injecting a semaglutide product.
Banks have noticed. A Global Legal Law Firm clip describes banks flagging merchants that onboarded as research labs for a "violation of standards," on the belief that "a doctor's prescription needs to be involved." The products had not changed. Even one payment vendor's own marketing concedes that peptide sellers get sorted into high risk by category code rather than by their chargeback history.
The common assumption is that a clean disclaimer keeps the account safe. It does not. Our underwriting team makes the same point about other high-risk verticals: a processor is not pricing the product name, it is pricing the shape of the business. An analysis of 4 sources shows one pattern. The label stays put. The buyer decides.
That is why any serious conversation about merchant payment processing solutions for peptides starts with your buyer list, and with how differently a lab order and a consumer order look to the people reading your file.
Who does a research-use-only label say is buying, and who actually is?
A research-use-only label makes a promise about who is buying. Federal drug rules spell out what that promise means, and a consumer peptide store's sales often tell another story.
The wording comes from 21 CFR 312.160, the federal rule on drugs shipped for laboratory research. Such a drug must carry a caution ending "Not for use in humans," and the shipper must "use due diligence to assure that the consignee is regularly engaged in conducting such tests." The shipper must also keep a record of each recipient, address, date, quantity and batch for 2 years. The exemption depends on who receives the drug as much as on what the label says.
The label leaves out one kind of buyer. C. Michael White, a UConn pharmacist and clinical pharmacologist who studies gray-market peptides, notes that sellers using the "for research purposes only" label cannot legally tell buyers how to use what they sell. His team published a study in Public Health Reports in which 20 people, 10 college students and 10 adults in their 60s, tried to reconstitute a semaglutide product and inject a mannequin. On average, both groups got fewer than half the steps right.
"This means consumers must purchase any supplies they need and figure out the proper technique on their own."
C. Michael White, UConn pharmacist and clinical pharmacologist, 2026
White's study measured injection safety and says nothing about payments. What it does show is the gap: a label naming a laboratory, on a product that individuals buy and use on themselves.
Some banks have started treating research-lab sellers as if they sold prescription drugs. In an April 2025 video, a speaker for Global Legal Law Firm described peptide merchants who told their banks "We're a research lab," passed onboarding, and were later flagged for a "violation of standards." According to the speaker, the products had not changed. The banks had decided "a doctor's prescription needs to be involved" and applied that view to every peptide alike. The firm argues the merchants' side, and one short clip cannot show how widely banks think this way.
People who place merchants with banks draw the line by buyer. In a 2024 payment-processing forum thread, one commenter wrote that "there are two types of peptide companies: telehealth providers and general peptide merchants." The same commenter said sellers of peptides alone need a proven history of six-figure monthly volume before card processing is realistic, and that it stays hard even then. A 2026 commenter put research-only consumer sellers firmly on the losing side of that line. In that view, the consumer route that gets approved runs through telemedicine, prescriptions and LegitScript certification.
The Precision Peptide Company, which routes prescriptions through telehealth, announced LegitScript Healthcare Merchant Certification on June 23, 2026. Yazan Homsi, a newsletter writer who covers the company as an investment, explained why it matters: without it, "a peptide company can build the best product in the world and still struggle to accept credit cards or run paid ads."
Sellers who stay on the consumer research side describe something less durable. One founder in the February 2026 thread ran a business processing at most $10k a month. Every major mainstream platform it tried banned it within about two weeks, and the next processor dropped all peptide accounts the day after boarding it. On its current processor, more than 70% of card payments fail fraud screening.
| Question | Lab or institutional buyer | Consumer under a research label |
|---|---|---|
| What the federal rule expects | A recipient "regularly engaged" in lab tests, with records kept 2 years | The same "Not for use in humans" caution on a product bought for personal use |
| Who handles the product | Researchers running tests | Individuals who, in one 20-person study, got fewer than half the injection steps right |
| What practitioners report | B2B, large-ticket sales from an FDA-approved facility can be processed | Merchant IDs that last two to three months; a large seller kept card processing for "a couple months" |
| Route practitioners call approvable | Documented B2B supply | Telehealth prescriptions with LegitScript certification |
Not everyone agrees the door is shut. One provider in the 2024 thread said it was boarding "quite a few 'research only' peptide merchants," though only in the UK and EU, and several commenters offered placements by private message. Many of these voices sell the service they describe. Their reports show what practitioners see, but they cannot show how often any route succeeds.
Side by side, the regulation, the study and the forum reports describe one contradiction. The label names a lab as the buyer, while a consumer storefront's orders name individuals. The disclaimer was always a claim about the customer, and in these accounts processors want to see that customer for themselves. None of our sources tested whether splitting a mixed business into separate lab and consumer storefronts, each with its own merchant account, wins approval by itself.
- Sort recent orders into institutional buyers and individual cardholders. Practitioners say the B2B, large-ticket share is what processors will board.
- For lab sales, keep the records the federal rule describes: recipient, address, date, quantity and batch. Ask counsel whether the rule covers your catalog.
- Describe your real buyers on the application. The merchants in the 2025 clip passed onboarding as research labs and were flagged later.
- If consumers are a real share of sales, ask whether a telehealth prescription model with LegitScript certification fits your business.
- Ask any processor offering consumer research-only processing how long its peptide merchant IDs have lasted, and whether separate lab and consumer accounts would change its answer.
How we checked this
We read the federal regulation on drugs shipped for lab research, a UConn summary of a peer-reviewed self-injection study, a 2025 video from a law firm arguing the merchants' side, two payment-processing forum threads from 2024 and 2026, and a 2026 investment newsletter. None of the figures in this section come from our own data. The forum reports are unverified, and many commenters sell processing placements. The newsletter covers a listed company as an investment. The study had 20 participants and measured injection skill. It did not look at payments. We are a high-risk payment processor that works with peptide sellers, so we have a stake in this answer. Still unknown: whether separating lab and consumer sales onto different accounts changes approval on its own, and how often banks revisit peptide merchants they have already approved.
- Electronic Code of Federal Regulations via Cornell Law School, 21 CFR 312.160 on lab research drugs, retrieved October 24, 2026.
- UConn Today, C. Michael White on DIY peptide injections, August 21, 2026.
- Global Legal Law Firm, video on banks and research peptide merchants, April 2025.
- r/PaymentProcessing, forum thread on peptide payment processors, February 2026.
- r/PaymentProcessing, forum thread on peptide processing, November 2024.
- Yazan Homsi, newsletter on a peptide company's LegitScript certification, June 2026.
How do underwriters tell a lab-supply peptide seller from a consumer one?
They read the buyer, the order and the storefront. Lab supply looks institutional and documented, while consumer sales look like personal use under a research label.
Practitioners have been drawing this line for a while. In a 2024 r/PaymentProcessing thread, one commenter said there are "two types of peptide companies: telehealth providers and general peptide merchants," and that many providers pitching peptide sellers did not know there was a difference. A February 2026 thread on the same forum sharpened it: a commenter said B2B, large-ticket sales from an FDA-approved facility can still get legitimate processing, while research-only sellers have "no legit path."
| Signal | B2B lab and institutional channel | Direct-to-consumer research-use-only channel |
|---|---|---|
| Who buys | Pharma and biotech firms, research institutes, contract research organizations | Individual shoppers |
| Order shape | Larger tickets, repeat institutional accounts | Small, frequent retail orders |
| Does the label fit the buyer? | Yes, research use matches the customer | No, the buyer's real use sits outside the label |
| Practitioner view of a card path | Possible from an FDA-approved facility | Described as having no legitimate path |
The institutional side is a real market. One industry report groups peptide end users into pharmaceutical and biotech companies, academic and research institutes, and contract research organizations. Those buyers can show who they are. A consumer usually cannot.
The consumer side has its own regulated route, and it runs through certification rather than disclaimers. One consumer-focused peptide company announced LegitScript Healthcare Merchant Certification on June 23, 2026, which it says Visa, Mastercard, Google, Microsoft and Meta recognize.
Here is how I read it. A store that mixes both columns gets judged by the riskier one. Clean lab orders do not rescue a consumer storefront sitting on the same account. That is the lens to bring to any peptide merchant account application, and it shapes exactly what you will need on file before an underwriter says yes.
What does a peptide merchant need to get approved, and what reserves should it expect?
Approval starts with established volume of at least $25,000 a month, then a clean split between lab and consumer sales. Plan for reserves either way.
At SeamlessChex, our review starts from that volume floor. We work with established businesses, not pre-launch startups, and the $25,000 monthly minimum applies across every vertical, peptides included. From there, I would prepare five things before you apply:
- Put lab and institutional orders on their own storefront, under their own merchant ID, apart from any consumer sales.
- Gate the B2B checkout behind a business account so every order carries a company name and buyer contact.
- Keep trial-backed peptide products and wellness peptides in separate catalogs.
- Have recent processing statements ready that show steady volume by channel.
- Budget for a reserve and funding holds while the account seasons.
Why separate catalogs? Dr. Jess Steier of Unbiased Science draws the line clearly: approved peptide drugs such as insulin and GLP-1s rest on decades of trials, while wellness peptides like BPC-157 and TB-500 mostly have little or no human data. An underwriter sees that same gap in your product list.
Volume still matters for anyone selling only peptides. A 2024 r/PaymentProcessing commenter said card processing for peptide-only sellers was not an option without a proven six-figure-plus monthly history, and was tough even then. Reserves are the other cost. One payment vendor's own pitch claims high-risk processors hold 10% or more for 6 to 12 months; treat that as a vendor's framing, not a quote from your future processor.
Ask each processor you talk to whether its approval rates differ for split and mixed peptide applicants. That comparison is not on record yet. What I can say is that a clean split gives an underwriter one clear story per account. Mixed stores make them guess.
Sellers who already run serious volume through the lab channel should look at high-volume credit card processing for that side first, then decide whether the consumer storefront earns a merchant ID of its own.
Where is the peptide approval split heading next?
Toward the buyer. Processors will likely keep weighing who purchases a peptide over what its label says, so sellers who separate lab and consumer channels now face fewer surprises.
The two markets are pulling apart. In the University of Illinois Gardner survey from February 2025, 12.0% of respondents said they were currently using a GLP-1 medication. On the regulated side, more than 80 peptide drugs had gained international approval as of 2023. I would rather a seller walk into underwriting with that line already drawn, starting with how its credit card processing is set up for each channel.
Frequently Asked Questions
What else do peptide sellers ask about processor approval?
Most follow-up questions cover onboarding speed, where the lab market is heading, where consumer demand actually flows, and how payments can be taken once approved.
How fast can an established peptide seller get onboarded?
We offer same-day onboarding with no contracts. Approval still runs through underwriting. Having your lab and consumer channels documented before you apply makes that review faster. Start at seamlesschex.com/contact.
Is the lab-supply side of the peptide market growing?
Yes. Research Nester estimates the peptide synthesis market at USD 6.3 billion in 2026 and projects it will reach USD 12.2 billion by 2035. Most of that demand comes from pharmaceutical buyers, the side I would want to show an underwriter first.
Where does consumer GLP-1 spending go?
Mostly through prescriptions. A 2024 study found GLP-1 spending grew from USD 13.7 billion in 2018 to over USD 71.7 billion in 2023, with retail pharmacies accounting for more than 70% of that increase.
What does research-use-only actually mean for a seller?
Research-use-only (RUO) is a label stating a product is sold for laboratory research, not human use. It keeps a seller from telling buyers how to use the product. It says nothing about who those buyers are.
Can approved merchants take payments online and in person?
Yes. We support credit card processing first, with ACH as a second rail, both online and in person.
Written by
Lily Flanigan
Operations Manager, SeamlessChex
Lily Flanigan is Operations Manager at SeamlessChex, a credit card processing and fintech payments platform recognized on the Inc. 5000, where she focuses on operations and process optimization.
Connect on LinkedInSeamlessChex works with established businesses processing a minimum of $25,000 per month.